Summary
In addition to the well-known quinidine metabolites, 2’-quinidinone and 3-hydroxy-quinidine, a third metabolic product was detected in the plasma of cardiac patients receiving quinidine therapy. Mass spectroscopic,13C- and1H-NMR studies, together with information on UV and IR properties of the isolated and also synthetically accessible compound, suggested the presence of an aliphatic N-oxide group. The structure of quinidine-N-oxide for the hitherto unknown metabolite was finally confirmed by X-ray diffraction analysis. Evidence was found to indicate that a contaminant in quinidine preparations, dihydro-quinidine, is metabolized with respect to N-oxidation in the same way as quinidine.
This is a preview of subscription content, log in via an institution to check access.
Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Similar content being viewed by others
References
Ueda C.T., Hirschfeld D.S., Scheinmann M.M., Rowland M., Williamson B.J. and Dzindzio B.S. (1976): Disposition kinetics of quinidine. Clin. Pharmacol. Ther.,19, 30–36.
Ueda C.T. and Dzindzio B.S. (1978): Quinidine kinetics in congestive heart failure. Clin. Pharmacol. Ther.,23, 158–164.
Houston A.B. and Perry W.F. (1950): The plasma concentration of quinidine after oral administration and its effect on auricular fibrillation. Canad. Med. Assoc. J.,63, 56–60.
Brodie B.B., Baer J.E. and Craig L.C. (1951): Metabolic products of the cinchona alcaloids in human urine. J. Biol. Chem.188, 567–581.
Palmer K.H., Martin B., Baggett B. and Wall M.E. (1969): The metabolic fate of orally administered quinidine gluconate in humans. Biochem. Pharmacol.18, 1845–1860.
Carroll F.I., Smith D. and Wall M.E. (1974): Carbon-13 magnetic resonance study. Structure of the metabolites of orally administered quinidine in humans. J. Med. Chem.17, 985–987.
Beermann B., Leander K. and Lindström B. (1976): The metabolism of quinidine in man: Structure of a main metabolite. Acta Chem. Scand.30, 465.
Drayer D.E., Cook C.E. and Reidenberg M.M. (1976): Active quinidine metabolites. Clin. Res.24, 623A.
Drayer D.E., Lowenthal D.T., Restivo K.M., Schwartz A., Cook C.E. and Reidenberg M.M. (1978): Steadystate serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function. Clin. Pharmacol. Ther.24, 31–39.
Leferink J.G., Maes R.A.A., Sunshine I. and Forney R.B. (1977): A novel quinidine metabolism in a suicide case with quinidine sulphate detected by gas chromatography-mass spectrometry. J. Anal. Toxicol.1, 62–65.
Guentert T.W., Rakhit A., Upton R.A. and Riegelman S. (1980): An integrated approach to measurements of quinidine and metabolites in biological fluids. J. Chromatogr.183, 514–519.
Barrow S.E., Taylor A.A., Horning E.C. and Horning M.G. (1980): High-performance liquid chromatographic separation and isolation of quinidine and quinine metabolites in rat urine. J. Chromatogr.181, 219–226.
Watabe T. and Kiyonaga K. (1972): The metabolic fate of quinine in rabbits. J. Pharm. Pharmacol.24, 625–630.
Jovanović J., Remberg G., Ende M. and Spiteller G. (1976): Quinine-N-oxide- A urinary component after the consumption of quinine beverages. Arch. Toxicol.32, 137–139.
Guentert T.W., Coates P.E., Upton R.A., Combs D.L. and Riegelman S. (1979): Determination of quinidine and its major metabolites by high-performance liquid chromatography. J. Chromatogr.162, 59–70.
K. Fischer (1935): Neues Verfahren zur massanalytischen Bestimmung des Wassergehaltes von Flüssigkeiten und festen Körpern. Angew. Chemie48, 394–396.
Bild N. and Hesse M. (1976): Notiz über die Massenspektren von N-Oxiden. Helv. Chim. Acta50, 1885–1892.
Biemann K. (1962): Mass Spectrometry. Mc Graw-Hill, New York, pp. 134–137.
Spiteller G. and Spiteller-Friedmann M. (1963): Schlüsselbruchstücke in den Massenspektren von Alkaloiden. Tetrahedr. Lett.3, 153–158.
Budzikiewicz H., Djerassi C. and Williams D.H. (1964): Structure elucidation of natural products by mass spectrometry. Holden-Day Inc., San Francisco, vol. I. pp. 220–222.
Interatomic Distances, Special Publication No 18, The Chemical Society, London (1955).
Nimmo J.K. and Lucas B.W. (1976): Solid state phase transition in triethylenediamine, N(CH2CH2)3 N. I. The crystal structure of phase II at 2980K. Acta Cryst. B32, 348–353.
Caron A., Palenik G.J., Goldish E. and Donohue J. (1964): The molecular and crystal structure of trimethylamine oxide (CH3)3NO. Acta Cryst.17, 102–108.
Wenkert E., Bindra J.S., Chang C.-J., Cochran D.W. and Schell F.M. (1974): Carbon-13 nuclear magnetic resonance spectroscopy of naturally occurring substances. Alcaloids. Acc. Chem. Res.7, 46–51.
Low K.L. and Castagnoli N. (1980): Drug Biotrans-formations. In Burgers’s Medicinal Chemistry, 4th ed., part I, Wolff M.E. (ed.), John Wiley & Sons, New York.
Bickel M.H. (1969): The pharmacology and biochemistry of N-oxides. Pharmacol. Rev.21, 325–355.
Bickel M.H. (1972): Liver metabolic reactions: Tertiary amine N-dealkylation, tertiary amine N-oxidation, N-oxide reduction, and N-oxide N-dealkylation. Arch. Biochem. Biophys.148, 54–62.
Bickel M.H. (1971): N-oxide formation and related reactions in drug metabolism. Xenobiotica1, 313–319.
Polonovski M., Nayrac P. and Tiprez J. (1930): The N-oxide of morphine in therapeutics. Bull. Acad. Nat. Med.103, 174–178.
Fennessy M.R. (1968): The analgesic action of morphine-N-oxide. Brit. J. Pharmacol.34, 337–344.
Author information
Authors and Affiliations
Additional information
Deceased, April 4, 1981.
Rights and permissions
About this article
Cite this article
Guentert, T.W., Daly, J.J. & Riegelman, S. Isolation, characterisation and synthesis of a new quinidine metabolite. European Journal of Drug Metabolism and Pharmacokinetics 7, 31–38 (1982). https://doi.org/10.1007/BF03189540
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189540